George Church spinout GRObio explores strategic alternatives 6 months after $60M series B
Synthetic biology specialist Gro Biosciences, born out of the George Church Lab at Harvard, is exploring strategic alternatives only about half a year after raising a series B backed by top venture capital funds, Fierce Biotech has learned.
